SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as its highly engaged community champions the "OG meme" narrative, positioning Rage Comics as a foundational "meme reset" for the current market cycle. This dedicated base expresses strong conviction, actively building an ecosystem with platforms like RageMaker and RageGames, and urging enthusiasts to "Return to the Memes" and "Rage On" to reclaim leadership in the meme coin space.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

Starknet is gaining significant attention due to its expanding Bitcoin (BTC) staking and a surge in on-chain activity, evidenced by new highs in app revenue and Total Value Locked. The community is actively discussing its unique quantum-resistant ZK-rollup technology and native Account Abstraction, positioning it as a pivotal infrastructure for both the Ethereum and Bitcoin ecosystems.

The future is now. ZygoSwap a decentralized exchange (DEX) on the BNB Chain, providing a fully optimized and customizable trading for any BNB-listed tokens. Key Features: 1. Lowest swapping and trading fees. 2. $ZYGO holders receive 50% reduced fees on swaps and liquidity provision (no minimum holding required). 3. Zero fees for swapping or trading $ZYGO itself. 4. Ability to swap, buy, trade, and provide liquidity for any token on the BNB Chain. 5. Mobile-friendly interface for seamless on-the-go use. 6. ZSwap liquidity rewards token and staking options for additional earnings.  Benefits: 1. Cost-efficient for frequent traders and liquidity providers due to significantly lower fees. 2. Deflationary, Fees generated are used to buy back and burn $ZYGO &amp; $ZSWAP tokens. 3, Enhanced incentives for $ZYGO holders, including reduced costs and future rewards/staking yields. 4. Rewards for large swaps/buys and community engagement (e.g., airdrops for retweets/follows). 5. Optimized offering faster, cheaper transactions in the BNB Chain DeFi ecosystem.

ZygoSwap

ZygoSwap ($ZSWAP) is gaining significant community traction as users enthusiastically discuss its active development team and the operational ZygoSwap DEX. Many are highlighting its unique 'memetility' and perceived undervaluation as a micro-cap project offering practical utility, such as low-fee swaps. The strong engagement and ongoing building efforts are central to the bullish sentiment circulating within the community.

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. It currently advancing its Bria-IMT™ targeted immunotherapy in combination with an immune check point inhibitor in a pivotal 1 Phase 3 study in metastatic breast cancer. The company was founded by Charles L. Wiseman and Isaac Benjamin Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

BriaCell Therapeutics Corp - Ordinary Shares - New

BriaCell Therapeutics Corp

BriaCell Therapeutics is currently trending due to recent positive clinical data, including a sustained complete resolution of lung metastasis in a breast cancer patient, and a new NCI grant advancing its prostate cancer immunotherapy. However, community sentiment is sharply divided, with enthusiasm for the scientific breakthroughs tempered by widespread concern over a history of significant stock dilution and reverse splits. Discussions are heavily focused on the implications of recent public offerings and a reverse stock split, as the company seeks to fund its ongoing and promising clinical trials.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is garnering significant attention as analysts cite robust hyperscaler demand nearly depleting its server CPU supply and improved yields for its advanced manufacturing nodes. The community is actively discussing a major foundry customer win, which, alongside its perceived undervaluation and strategic role in domestic chip production, is fueling strong sentiment for a long-term turnaround.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is trending after a major bank issued a "Sell" rating, citing concerns over shrinking profit margins despite its strong position in the AI server market. The community is sharply divided, with many viewing the downgrade as strategic manipulation to acquire cheaper shares ahead of anticipated strong earnings. Bulls highlight the company's critical role in AI infrastructure and robust revenue growth, while bears focus on profitability challenges and management's perceived missteps.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending following robust Q4 revenue estimates and strong 2026 guidance for its MS drug Briumvi, with many in the community anticipating it will achieve blockbuster status sooner than projected. Investors are highlighting Briumvi's best-in-class efficacy and safety profile, especially as a key competitor recently faced regulatory setbacks due to safety concerns. This solidifies Briumvi's market position and fuels ongoing discussions about future growth catalysts, including a potential Sub-Q formulation and M&A interest.

Semler Scientific, Inc. engages in the provision of technology and software solutions to improve the clinical effectiveness of healthcare providers. Its multi-test service platform, WellChec, comprehensively evaluates its customers’ patients for chronic disease, including heart attacks and strokes, using its QuantaFlo product as well as other tests. The company was founded by Herbert J. Semler, Guinasso Cindy and Shirley L. Semler on August 9, 2007 and is headquartered in Campbell, CA.

Semler Scientific Inc

Semler Scientific is trending due to its imminent shareholder vote on a transformative merger with Strive, aiming to establish one of the largest public Bitcoin treasury companies. Community discussion focuses on the proposed share exchange and the combined entity's substantial Bitcoin holdings, weighing potential arbitrage against historical volatility and concerns regarding dilution and management. Investors are actively debating the long-term implications for shareholder value as both companies pivot towards a digital asset treasury model.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending amid significant price volatility and heavy trading volume, driven by community debate surrounding recent insider stock sales and market interpretations of new AI agent competition. While many investors view the current dip as a prime accumulation opportunity given the company's robust financials and strategic position in agentic AI, others express caution regarding persistent insider selling and the evolving competitive landscape in the software sector.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending due to mixed signals, with recent analyst downgrades and a vehicle recall contributing to immediate selling pressure. Despite this, significant community attention is focused on the highly anticipated R2 launch, which many view as a pivotal catalyst for the company's long-term success. Investors are actively debating whether current price levels represent a buying opportunity, banking on the R2 to broaden market appeal and advance Rivian's position in the competitive EV and software-defined vehicle landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

XOMA Royalty CFO Thomas Burns To Resign, Jeffrey Trigilio To Be New CFO

(RTTNews) - XOMA Royalty Corp. (XOMA), Monday announced that its Chief Financial Officer, Thomas Burns, has decided to step down from his position to pursue other professional opportunities...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA...

Implied Volatility Surging for XOMA Royalty Stock Options

Investors need to pay close attention to XOMA stock based on the movements in the options market lately.

XOMA Royalty Corporation (NASDAQ:XOMA) Given Average Rating of "Hold" by Analysts

Shares of XOMA Royalty Corporation (NASDAQ:XOMA - Get Free Report) have received a consensus rating of "Hold" from the five analysts that are currently covering the firm, MarketBeat reports. One...

XOMA Royalty Corporation (NASDAQ:XOMA) Short Interest Up 31.7% in December

XOMA Royalty Corporation (NASDAQ:XOMA - Get Free Report) saw a significant growth in short interest during the month of December. As of December 15th, there was short interest totaling 482,452...

FY2025 EPS Estimates for XOMA Royalty Reduced by Analyst

XOMA Royalty Corporation (NASDAQ:XOMA - Free Report) - Analysts at HC Wainwright decreased their FY2025 earnings per share (EPS) estimates for XOMA Royalty in a research report issued on Thursday...

BVF Inc. IL Has $65.28 Million Stock Position in XOMA Royalty Corporation $XOMA

BVF Inc. IL lowered its holdings in XOMA Royalty Corporation (NASDAQ:XOMA - Free Report) by 13.2% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned...

XOMA Royalty Corporation (NASDAQ:XOMA) Receives Average Rating of "Hold" from Brokerages

XOMA Royalty Corporation (NASDAQ:XOMA - Get Free Report) has received an average recommendation of "Hold" from the five brokerages that are presently covering the stock, MarketBeat Ratings reports...

Why Is XOMA Royalty Stock Sinking Thursday?

XOMA stock plunged after its partner Rezolute Inc. reported disappointing trial results for their product Ersodetug.read more...

XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with various assets that provides right to future potential royalty and milestone payments. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.

XOMA Royalty Corp.

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

Current Price	$27.14
Prev Close	$26.79
Open	$26.59
Dividend Yield	0.00%
50-Day Moving Average	$29.74
Beta	0.77
Avg. Volume	166,725.09
PE Ratio	36.41

52-Week High	$39.92
52-Week Low	$18.35
Market Capitalization	$331.74M
EPS (Annual)	-$1.65
Price to Book	3.80
Revenue Per Employee	$2.19M
Enterprise Value/EBITDA	N/A

XOMA
XOMA Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest XOMA News

XOMAXOMA Corp